Compare Stocks: KVAC, RCKT, GALT, and CABA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.61 +8.8%	$2.57	$1.39 ▼ $4.23	$272.96M	3.48	4.17 million shs	3.46 million shs
GALT Galectin Therapeutics	$3.43 -1.7%	$3.85	$2.03 ▼ $7.13	$225.90M	0.38	426,929 shs	200,199 shs
KVAC Keen Vision Acquisition	$11.51	$11.51	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
RCKT Rocket Pharmaceuticals	$2.34 +4.5%	$3.16	$2.16 ▼ $5.45	$256.89M	0.5	2.53 million shs	1.89 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+4.96%	-17.32%	-41.96%	-47.52%	-48.07%
GALT Galectin Therapeutics	-3.59%	-9.82%	-10.28%	-9.35%	-30.06%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-6.23%	-0.99%
RCKT Rocket Pharmaceuticals	+2.75%	-9.68%	-33.53%	-34.12%	-39.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.61 +8.8%	$2.57	$1.39 ▼ $4.23	$272.96M	3.48	4.17 million shs	3.46 million shs
GALT Galectin Therapeutics	$3.43 -1.7%	$3.85	$2.03 ▼ $7.13	$225.90M	0.38	426,929 shs	200,199 shs
KVAC Keen Vision Acquisition	$11.51	$11.51	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
RCKT Rocket Pharmaceuticals	$2.34 +4.5%	$3.16	$2.16 ▼ $5.45	$256.89M	0.5	2.53 million shs	1.89 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+4.96%	-17.32%	-41.96%	-47.52%	-48.07%
GALT Galectin Therapeutics	-3.59%	-9.82%	-10.28%	-9.35%	-30.06%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-6.23%	-0.99%
RCKT Rocket Pharmaceuticals	+2.75%	-9.68%	-33.53%	-34.12%	-39.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	2.89	Moderate Buy	$15.60	868.94% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	220.70% Upside
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A
RCKT Rocket Pharmaceuticals	2.42	Hold	$7.77	232.15% Upside

Current Analyst Ratings Breakdown

Latest KVAC, RCKT, GALT, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell ➝ Neutral	$3.00 ➝ $4.00
10/7/2026	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/7/2026	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$2.95
10/7/2026	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$7.00 ➝ $4.00
10/7/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/7/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$11.00
9/23/2026	CABA Cabaletta Bio	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/16/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$15.00
9/16/2026	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$9.00
9/15/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$11.00

(Data available from 10/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)

Latest KVAC, RCKT, GALT, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	GALT Galectin Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	CABA Cabaletta Bio	-$0.33	N/A	N/A	N/A	$1.67 million	N/A
11/5/2026	Q3 2026	RCKT Rocket Pharmaceuticals	-$0.39	N/A	N/A	N/A	$0.20 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	5.79	5.79
GALT Galectin Therapeutics	N/A	0.10	0.10
KVAC Keen Vision Acquisition	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
GALT Galectin Therapeutics	11.68%
KVAC Keen Vision Acquisition	51.72%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	6.44%
GALT Galectin Therapeutics	53.00%
KVAC Keen Vision Acquisition	80.20%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	158	169.54 million	158.63 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	30.95 million	Optionable
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable
RCKT Rocket Pharmaceuticals	202	109.78 million	86.39 million	Optionable

KVAC, RCKT, GALT, and CABA Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Breaks Below Fifty Day Moving Average - What's Next?

October 20 at 4:01 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below 50 Day Moving Average - Time to Sell?

October 20 at 3:59 AM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock Has Average Price Target of $7.77 According to Brokerages

October 10, 2026 | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock Rated "Hold" by Wall Street Analysts

October 10, 2026 | marketbeat.com

Rocket Pharmaceuticals Inc (RCKT)

October 9, 2026 | za.investing.com

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)

October 9, 2026 | theglobeandmail.com

Wedbush Reaffirms "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

October 9, 2026 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Target Cut by Leerink Partners

October 9, 2026 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $4.00 by Analysts at Leerink Partners

October 7, 2026 | marketbeat.com

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

October 7, 2026 | proactiveinvestors.com

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

October 7, 2026 | businesswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed as Outperform by Wedbush

October 7, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Given Buy Rating at Chardan Capital

October 7, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

October 7, 2026 | seekingalpha.com

Transcript : Rocket Pharmaceuticals, Inc. - Special Call

October 7, 2026 | marketscreener.comM

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

October 6, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT)

October 3, 2026 | theglobeandmail.com

Rocket Pharmaceuticals, Inc. $RCKT Shares Newly Acquired by Bank of America Corp DE

October 1, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Below 50-Day Moving Average - Here's Why

September 29, 2026 | marketbeat.com

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

September 22, 2026 | insidermonkey.com

Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

September 18, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, RCKT, GALT, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.61 +0.13 (+8.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 -0.02 (-1.49%)

As of 06:53 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Galectin Therapeutics NASDAQ:GALT

$3.43 -0.06 (-1.72%)

As of 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 10/19/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.34 +0.10 (+4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.03 (+1.41%)

As of 05:53 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KVAC, RCKT, GALT, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KVAC, RCKT, GALT, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KVAC, RCKT, GALT, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, RCKT, GALT, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Galectin Therapeutics NASDAQ:GALT

Keen Vision Acquisition NASDAQ:KVAC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KVAC, RCKT, GALT, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KVAC, RCKT, GALT, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KVAC, RCKT, GALT, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, RCKT, GALT, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Galectin Therapeutics NASDAQ:GALT

Keen Vision Acquisition NASDAQ:KVAC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools